In Q1 2023, OrbiMed Advisors held 80 positions worth $4.0B. They initiated 80 new positions. Their largest holding was SVA ($340.0M).
Frequently asked questions
What stocks did OrbiMed Advisors own in Q1 2023?
OrbiMed Advisors held 80 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include SVA, ELVN, BSX, HUM, ISRG. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was OrbiMed Advisors's portfolio worth in Q1 2023?
OrbiMed Advisors's tracked biotech portfolio was worth $4.0B across 80 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
What did OrbiMed Advisors buy in Q1 2023?
OrbiMed Advisors initiated 80 new positions in Q1 2023, including SVA, ELVN, BSX, HUM, ISRG and 75 more. They also increased 0 existing positions.
What did OrbiMed Advisors sell in Q1 2023?
OrbiMed Advisors did not fully exit any positions in Q1 2023.
Is OrbiMed Advisors a biotech fund?
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Want AI analysis, insider signals, and catalyst overlays for OrbiMed Advisors?
View latest OrbiMed Advisors portfolio →